Clinical trials: Subcutaneous Fat
Subcutaneous Fat
A Study to Evaluate the Efficacy and Safety of CBL-514 Injection for Reducing Subcutaneous Fat ( SUPREME-02 )
A phase 3, randomized, double-blinded, placebo-controlled study to evaluate the efficacy, safety, and tolerability of CBL-514 injection for reducing abdominal subcutaneous fat.
- Trial name
- NCT07526974
- Testing
- CBL-514 Injection, 0.9% Sodium Chloride
- Where
- 14 sites in United States, Australia and 1 more
- Volunteers
- 320 people, healthy volunteers welcome
- Sponsor
- Caliway Biopharmaceuticals Co., Ltd.
Subcutaneous Fat
A Study to Evaluate the Efficacy, Safety, and Tolerability of CBL-514 Injection for Reducing Abdominal Subcutaneous Fat
A phase 2b, randomized, placebo-controlled study with long-term re-treatment to evaluate the efficacy, safety, and tolerability of CBL-514 injection for reducing abdominal subcutaneous fat.
- Trial name
- NCT07608757
- Testing
- CBL-514 Injection
- Where
- Australia
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Caliway Biopharmaceuticals Co., Ltd.
Subcutaneous Fat
A Study to Evaluate the Efficacy, Safety, and Tolerability of CBL-514 Injection for Reducing Abdominal Subcutaneous Fat
A phase 2b, randomized, placebo-controlled study with long-term re-treatment to evaluate the efficacy, safety, and tolerability of CBL-514 injection for reducing abdominal subcutaneous fat
- Trial name
- NCT07608770
- Testing
- CBL-514 Injection, 0.9% Sodium Chloride
- Where
- Australia
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Caliway Biopharmaceuticals Co., Ltd.
Subcutaneous Fat
A Study to Evaluate the Efficacy and Safety of CBL-514 Injection for Reducing Subcutaneous Fat
A phase 3, randomized, double-blinded, placebo-controlled study to evaluate the efficacy, safety, and tolerability of CBL-514 injection for reducing abdominal subcutaneous fat.
- Trial name
- SUPREME-01 (NCT07140939)
- Testing
- CBL-514 Injection, 0.9% Sodium Chloride
- Where
- 13 sites in United States, Canada
- Volunteers
- 320 people, healthy volunteers welcome
- Sponsor
- Caliway Biopharmaceuticals Co., Ltd.
Subcutaneous Fat
A Study to Evaluate the Maintenance of Efficacy and Long-term Safety of CBL-514 Injection for Reducing Subcutaneous Fat (Stage 1)
A Phase 3b, Multicenter, Two stage, Double-blind, Long term Follow up and Open-label Extension Study of Participants Who have Completed the CBL-0301 or CBL-0302 Study for Reducing Abdominal Subcutaneous Fat (Stage 1)
- Trial name
- NCT07733947
- Testing
- CBL-514 Injection, 0.9 % sodium chloride
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Caliway Biopharmaceuticals Co., Ltd.
Facial Subcutaneous Fullness, Subcutaneous Fat Accumulation
Efficacy and Safety of High-Dose Oral 35 kDa Hyaluronan for Aesthetic Improvement
This is a prospective, single-arm, open-label, pilot clinical study to evaluate the efficacy and safety of high-dose oral 70 kDa hyaluronan (HA35) for aesthetic improvement.
- Conditions
- Facial Subcutaneous Fullness, Subcutaneous Fat Accumulation, Facial Inflammatory Erythema, Dull Skin
- Trial name
- HA35-ORAL (NCT07583108)
- Testing
- High-Dose Oral 35 kDa Hyaluronan (HA35)
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Nakhia Impex LLC
Facial Subcutaneous Fat, Facial Erythema
Efficacy and Safety of Overnight Occlusive HA35 Gel for Facial Aesthetic Improvement
This is a prospective, single-arm, open-label, pilot clinical study to evaluate the efficacy and safety of overnight occlusive topical application of 10% high-concentration 35 kDa hyaluronan (HA35) gel for facial aesthetic…
- Conditions
- Facial Subcutaneous Fat, Facial Erythema, Skin Dullness, Nasal Alar Pore Enlargement
- Trial name
- HA35-FACIAL (NCT07584811)
- Testing
- 10% High-Concentration 35 kDa Hyaluronan (HA35) Facial Occlusive Gel
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Nakhia Impex LLC
Subcutaneous Fat
A Study to Evaluate the Pharmacokinetic Profile of CBL-514 Injection in Healthy Volunteers
This Phase 2 study will be an open-label and single course study to assess the safety, tolerability, PK and metabolite profile of CBL-514.
- Trial name
- NCT05234736
- Testing
- CBL-514
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Caliway Biopharmaceuticals Co., Ltd.
Subcutaneous Fat Disorder
Safety and Efficacy Study of 10XB-101 in Adults With Bilateral Flank Adiposity
The goal of this clinical trial is to test the safety and effectiveness of an injection study drug in decreasing bilateral flank adiposity.
- Trial name
- NCT05760248
- Testing
- 10XB-101 Solution for Injection, 6.0%
- Where
- 2 sites in United States
- Volunteers
- 13 people
- Sponsor
- 10xBio, LLC
Non-Alcoholic Fatty Liver Disease, Obesity, Morbid
Change of Adipose Tissues and Triglyceride After Bariatric Surgery or Life-style Intervention
The study is aimed To quantify the change of adipose tissues, triglyceride in liver and pancreas and cholesterol after lifestyle intervention or bariatric surgery.
- Conditions
- Non-Alcoholic Fatty Liver Disease, Obesity, Morbid, Brown Fat, Metabolic Disease
- Trial name
- NCT03875625
- Testing
- Bariatric surgery, Dietitian led life style modification intervention, Conventional care (control)
- Where
- Hong Kong
- Volunteers
- 80 people
- Sponsor
- Chinese University of Hong Kong
Subcutaneous Fat
A Phase 2b Study to Evaluate the Efficacy and Safety of CBL-514 Injection for Reducing Subcutaneous Fat.
This is a randomized, placebo-controlled, Phase 2b study to evaluate the efficacy, safety, and tolerability of CBL-514 injection compared with CBL-A1 and CBL-A2 for reducing subcutaneous fat.
- Trial name
- NCT06005441
- Testing
- CBL-514 injection, CBL-A1 Injection, CBL-A2 Injection
- Where
- United States
- Volunteers
- 173 people, healthy volunteers welcome
- Sponsor
- Caliway Biopharmaceuticals Co., Ltd.
Subcutaneous Fat
A Study to Evaluate the Efficacy, Safety and Tolerability of CBL-514 Injection for Reducing Subcutaneous Fat (Stage 1)
The Stage 1 of this phase 2 study is an open-label single ascending dose (SAD) study. The primary objectives are to evaluate the safety and tolerability of injection lipolysis with CBL-514.
- Trial name
- NCT04575467
- Testing
- CBL-514
- Where
- Australia
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Caliway Biopharmaceuticals Co., Ltd.
Subcutaneous Fat
A Study to Evaluate the Efficacy, Safety and Tolerability of CBL-514 Injection for Reducing Abdominal Subcutaneous Fat
This is a randomized, placebo-controlled, Phase 2b study to evaluate the efficacy, safety, and tolerability of CBL-514 injection for reducing subcutaneous fat.
- Trial name
- NCT05736107
- Testing
- CBL-514 Injection, 0.9% Sodium Chloride
- Where
- United States
- Volunteers
- 107 people, healthy volunteers welcome
- Sponsor
- Caliway Biopharmaceuticals Co., Ltd.
Subcutaneous Fat Disorder
Combination of Light and Ultrasound to Reduce Abdominal Fat
Light and ultrasound can be interesting alternatives to reduce abdominal fat. Thus, the main objective of this study will be to evaluate the effects of these isolated techniques and their association in subcutaneous abdominal…
- Trial name
- NCT05155683
- Testing
- Photobiomodulation (PBM) with infrared LED, Low-frequency ultrasound (LOFU), Muscle electrostimulation
- Where
- Brazil
- Volunteers
- 79 people, healthy volunteers welcome
- Sponsor
- University of Nove de Julho
Subcutaneous Fat
Diagnostic Ultrasound for Measuring Fat of the Body
The purpose of this study is to provide information about human subcutaneous fat thickness at different anatomic sites on the body by measuring these thicknesses with a diagnostic ultrasound and also by correlating patient…
- Trial name
- NCT03871556
- Testing
- LOGIQ P6 Diagnostic Ultrasound
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Northwestern University
Subcutaneous Fat Disorder
Subject Evaluation of a 1064nm Diode Laser/RF
Open-label, baseline-controlled, multi-center study evaluating a 1064 nm diode laser, pulsed electromagnetic fields and vacuum assisted radio frequency for non-invasive fat reduction of the abdomen and flanks.
- Trial name
- NCT04090853
- Testing
- Venus Bliss
- Where
- 3 sites in United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Venus Concept
Subcutaneous Fat
A Study to Evaluate the Efficacy, Safety, and Tolerability of CBL-514 Injection for Reducing Subcutaneous Fat (Stage 2)
The Stage 2 of this phase 2 study will be a randomized, single-blind, placebo-controlled, parallel, and multiple-dose study to assess the efficacy, safety, and subject satisfaction of CBL-514.
- Trial name
- NCT04897412
- Testing
- CBL-514 Injection
- Where
- 5 sites in United States, Australia
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Caliway Biopharmaceuticals Co., Ltd.
Abdominal Subcutaneous Fat
Low-Frequency, High-Intensity Ultrasound for Waist Circumference Reduction
This study evaluates the effectiveness and safety of externally applied lower frequency ultrasound to the waist/abdominal region of adults to achieve a reduction of fat cells/tissues below the skin, evidenced by a reduction in…
- Trial name
- NCT04206384
- Testing
- Ultrasound
- Where
- United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- CAO Group, Inc.
Subcutaneous Fat
A Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of CBL-514 Injection for Reducing Convexity or Fullness of Abdominal Subcutaneous Fat
The Phase 2a component of the study will be a randomized, open-label, parallel, and multiple dose study to further examine the safety and efficacy profile of 3 CBL-514 dose levels based on the results from Phase 1 of the study.
- Trial name
- NCT04698642
- Testing
- CBL-514
- Where
- Australia
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Caliway Biopharmaceuticals Co., Ltd.
Subcutaneous Fat
A Phase 1 Study to Evaluate the Safety and Tolerability of CBL-514 Injection on Convexity or Fullness of Abdominal Subcutaneous Fat in Healthy Volunteers
The Phase 1 component of the study is a double-blind, placebo-controlled, single ascending dose (SAD) design intended to assess the safety, tolerability, and PK of CBL-514. The SAD part will involve 9 proposed dosing cohorts.
- Trial name
- NCT04699669
- Testing
- CBL-514
- Where
- Australia
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Caliway Biopharmaceuticals Co., Ltd.